Related Experiment Video
Updated: May 12, 2026
06:26
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
Systemic metabolic dysfunction drives platelet-mediated inflammation, fibrogenesis, and hepatocarcinogenesis in
1Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Clinical and Molecular Hepatology
|May 10, 2026
Summary
Platelets play a key role in metabolic dysfunction-associated steatotic liver disease (MASLD) by worsening liver damage and inflammation. Targeting platelet activity may offer new treatments for MASLD.
Area of Science:
- Hepatology
- Immunology
- Metabolic Disorders
Background:
- Metabolic dysfunction-associated steatotic liver disease (MASLD) is a global health concern linked to metabolic disorders.
- Platelets, traditionally known for hemostasis, are emerging as key regulators of inflammation and immunity.
- The precise role of platelets in MASLD pathogenesis is not fully understood.
Purpose of the Study:
- To review current knowledge on platelet activation and recruitment in MASLD.
- To elucidate the mechanisms by which platelets contribute to MASLD progression, including steatosis, inflammation, fibrosis, and cancer.
- To evaluate the therapeutic potential of antiplatelet agents in MASLD.
Main Methods:
- Literature review synthesizing existing research on platelet function in MASLD.
- Examination of molecular and cellular mechanisms involved in platelet-MASLD interactions.
- Evaluation of preclinical and clinical data on antiplatelet therapies in MASLD.
Main Results:
- Metabolic disturbances and gut dysbiosis induce platelet hyperactivation and intrahepatic migration.
- Activated platelets exacerbate liver steatosis, amplify inflammation via immune cell interactions, and promote fibrosis through hepatic stellate cell activation.
- Platelets contribute to MASLD-associated hepatocellular carcinoma through inflammatory and direct tumor-regulatory pathways.
Conclusions:
- Platelet activation is a critical factor in MASLD pathogenesis and progression.
- Targeting platelet-related pathways presents a promising therapeutic strategy for MASLD.
- Antiplatelet agents, like aspirin, may help attenuate disease progression and associated complications.
Related Concept Videos
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
01:38Inflammation
Overview
01:24Overview of Lipid Metabolism
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
01:23Cirrhosis I: Introduction
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
01:12Chronic Inflammation: Introduction
Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...
01:26Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...